Seres Therapeutics (NASDAQ:MCRB) Downgraded to “Sell” Rating by StockNews.com

StockNews.com cut shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning.

MCRB has been the subject of several other research reports. Chardan Capital reissued a “buy” rating and set a $1.25 target price on shares of Seres Therapeutics in a research note on Wednesday, November 13th. Canaccord Genuity Group reissued a “buy” rating and issued a $10.00 price objective on shares of Seres Therapeutics in a research note on Thursday, November 14th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Seres Therapeutics presently has an average rating of “Hold” and an average price target of $5.08.

Seres Therapeutics Stock Performance

Seres Therapeutics stock opened at $0.73 on Tuesday. Seres Therapeutics has a 52 week low of $0.54 and a 52 week high of $1.53. The stock has a market capitalization of $124.30 million, a P/E ratio of -3.17 and a beta of 2.11. The stock has a fifty day moving average of $0.83 and a 200-day moving average of $0.84.

Institutional Trading of Seres Therapeutics

A number of hedge funds have recently made changes to their positions in MCRB. Avantax Advisory Services Inc. raised its holdings in Seres Therapeutics by 170.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 28,500 shares during the last quarter. Jane Street Group LLC increased its position in Seres Therapeutics by 181.4% in the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 37,866 shares during the period. Virtu Financial LLC raised its stake in shares of Seres Therapeutics by 44.8% during the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 18,191 shares during the last quarter. Providence Wealth Advisors LLC lifted its holdings in shares of Seres Therapeutics by 29.2% during the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 22,250 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Seres Therapeutics by 20.4% in the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock worth $218,000 after purchasing an additional 44,461 shares during the last quarter. 59.34% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.